Quinidine

Introduction Overview

Generic Name

quinidine

Brand Name

Quin-G, Cardioquin, Quinora, Quinidex Extentabs, Quinaglute Dura-Tabs, Quin-Release

Dosage Form

oral tablet (200 mg; 300 mg), oral extended-release tablet (324 mg), injection

Drug Class

Group I antiarrhythmics

Pharmacokinetics

Absorption:
Quinidine is well absorbed following oral administration, with bioavailability influenced by the formulation and gastric pH. Peak plasma concentrations typically occur within 1 to 3 hours for immediate-release tablets, while extended-release formulations provide a more gradual absorption profile, extending the peak concentration to 8 to 12 hours. Absorption can be affected by food intake and concomitant use of agents that modify gastric motility or pH. Grapefruit products significantly increase quinidine plasma levels by inhibiting intestinal CYP3A4, thereby enhancing absorption and potentially leading to toxicity. Clinically, monitoring plasma levels is critical due to the narrow therapeutic window.

Distribution:
Quinidine exhibits a moderate volume of distribution, approximately 2 to 4 L/kg, indicating extensive tissue binding. It is about 70% bound to plasma proteins, primarily albumin. The drug crosses the placental barrier and is also excreted in breast milk. Tissue distribution includes cardiac tissue, where therapeutic action is exerted, as well as the central nervous system, which relates to some neurological adverse effects. The distribution phase is rapid, but steady-state concentrations are typically reached within several days, emphasizing the need for dose adjustments in certain populations.

Metabolism:
Quinidine undergoes hepatic metabolism primarily via the cytochrome P450 system, notably CYP3A4 isoenzymes. It is metabolized to 3-hydroxyquinidine and other minor metabolites, which lack antiarrhythmic activity. Hepatic impairment can decrease clearance, necessitating dose modification. Quinidine is also a potent inhibitor of CYP2D6, which has significant implications for drug-drug interactions. First-pass metabolism affects oral bioavailability and is variable among individuals.

Elimination:
The elimination half-life of quinidine ranges between 6 to 8 hours in healthy adults but can be prolonged in hepatic or renal dysfunction. Approximately 20-30% of the drug is excreted unchanged via the kidneys, with the remainder eliminated as metabolites via biliary excretion. Renal clearance is influenced by urinary pH, with alkaline urine increasing quinidine elimination. Due to this dual elimination pathway, dosing adjustments are recommended in patients with impaired renal or hepatic function. Therapeutic drug monitoring assists in maintaining plasma concentrations within the therapeutic range.

Dosage Forms

Available Dosage Forms:
- Oral tablets: 200 mg, 300 mg immediate-release
- Oral extended-release tablets: 324 mg
- Injectable formulation for intravenous infusion (dosing individualized by healthcare provider)

Dosages for Adults and Adolescents:
For arrhythmia management, initial oral doses typically start at 200 mg to 300 mg every 6 to 8 hours, titrated based on clinical response and plasma levels. Extended-release tablets allow for less frequent dosing, usually twice daily. Intravenous quinidine is reserved for acute management when oral administration is not possible or during treatment of severe malaria infection, with dosing calculated by ideal body weight and closely monitored in a hospital setting.

Specific Patient Populations:
In hepatic or renal impairment, dosage reduction and cautious monitoring are necessary due to altered metabolism and elimination. Elderly patients may require lower or adjusted dosing due to increased susceptibility to side effects and pharmacokinetic changes. Pregnant patients should use quinidine only if clearly needed, with fetal monitoring advised. Breastfeeding is contraindicated due to drug excretion in milk and potential risk to the infant.

Clinical Guidelines:
Patients initiating quinidine therapy should be monitored with electrocardiographic evaluation and plasma drug level assessments to avoid proarrhythmic effects and toxicity. Dosing intervals may be adjusted based on therapeutic response and side effect profile. The extended-release formulation is not to be crushed or chewed to prevent dose dumping and associated adverse effects.

Mechanism Of Action

Quinidine is a class IA antiarrhythmic agent that primarily functions by blocking the fast inward sodium channels during phase 0 of the cardiac action potential. This blockage slows the rate of depolarization, thereby decreasing conduction velocity throughout the atrial and ventricular myocardium and the specialized conduction system, including the His-Purkinje network. The slowing of conduction helps to suppress abnormal automaticity and reentrant arrhythmias.

In addition to sodium channel blockade, quinidine exerts moderate blockade of potassium channels, prolonging the action potential duration and refractory period within myocardial cells. This delay in repolarization is responsible for the characteristic prolongation of the QT interval observed on electrocardiograms. Prolonging refractoriness is beneficial in interrupting reentrant circuits that often underpin arrhythmias but may predispose to torsades de pointes if excessive.

Quinidine also possesses anticholinergic properties by inhibiting vagal influences on the heart, leading to increased sinus node automaticity and atrioventricular conduction. This effect contributes to increased heart rate and may offset some bradycardic effects of arrhythmias but can complicate management in certain patients.

Several comparative studies indicate quinidine’s mechanism overlaps with other class IA agents like procainamide and disopyramide, though differences in potency and side effect profiles determine clinical selection. The extensive body of research indicates quinidine’s efficacy in suppressing many supraventricular and ventricular arrhythmias, although its proarrhythmic risks have relegated it to second-line use.

Pharmacological Actions

Blockade of fast inward sodium channels reducing myocardial excitability.
Prolongation of cardiac action potential and refractory period via potassium channel inhibition.
Moderate anticholinergic activity influencing heart rate and atrioventricular conduction.
Suppression of abnormal automaticity and conduction of reentrant arrhythmias.
Increase in sinus node automaticity due to vagolytic effects.
Decrease in conduction velocity across atrial and ventricular myocardium.
Prolongation of QT interval on electrocardiogram.
Inhibition of CYP2D6 enzyme affecting metabolism of other drugs.
Direct anti-malarial activity against Plasmodium falciparum.
Reduction in excitability contributing to antiarrhythmic efficacy.
Potential to cause proarrhythmic effects such as torsades de pointes under certain conditions.

Therapeutic Or Clinical Uses

Management of various cardiac arrhythmias including atrial fibrillation and flutter.
Treatment of ventricular arrhythmias such as ventricular tachycardia.
Suppression of premature atrial and ventricular contractions.
Acute treatment of life-threatening malaria caused by Plasmodium falciparum.
Used primarily when other antiarrhythmic medications have failed or are contraindicated.
Off-label use in certain supraventricular tachycardias refractory to other treatments.
Maintaining normal sinus rhythm post-cardioversion in atrial fibrillation patients.
Alternative therapy in patients intolerant to other class I and III antiarrhythmics.
Adjunctive therapy in complex arrhythmias requiring combination drug regimens.
Not proven to reduce mortality or stroke risk despite rhythm control properties.

Side Or Adverse Effects

Common chest pain or palpitations due to quinidine's cardiac effects.
Dizziness and vertigo related to central nervous system involvement.
Gastrointestinal disturbances: heartburn, nausea, vomiting, and diarrhea.
Flushing resulting from vasodilatory and histamine-release effects.
Fatigue and general weakness caused by drug systemic actions.
Local pain and tenderness at injection site persisting for weeks.
Cinchonism syndrome including tinnitus, hearing loss, headache, and visual disturbances.
Serious cardiac arrhythmias including torsades de pointes and QT prolongation.
Hypersensitivity reactions such as rash, photosensitivity, and anaphylaxis.
Hematological effects including bruising, bleeding tendency, and thrombocytopenia.
Hepatotoxicity presenting with jaundice, elevated liver enzymes, and abdominal pain.
Pulmonary toxicity with rare cases of interstitial pneumonitis.
Neurological symptoms including confusion, syncope, and seizure potential in overdose.
Muscle or joint pain possibly linked to autoimmune or inflammatory reactions.
Dry mouth and difficulty swallowing due to anticholinergic effects.

Precautions

Use cautiously in patients with pre-existing heart conditions, especially structural heart disease.
Close monitoring in patients with electrolyte imbalances, particularly hypokalemia or hypomagnesemia.
Avoid use in patients with AV block unless a pacemaker is present.
Monitor liver and renal function prior to and during treatment due to metabolism and excretion pathways.
Assess for history of myasthenia gravis as quinidine may worsen symptoms.
Caution with concomitant use of other QT-prolonging drugs and CYP2D6 substrates or inhibitors.
Regular ECG monitoring to detect QT prolongation or new arrhythmias.
Avoid use during pregnancy unless benefits outweigh risks; unknown fetal safety.
Discontinue in patients showing signs of hypersensitivity or severe adverse reactions.
Educate patients to report symptoms of hearing loss, visual changes, or severe dizziness immediately.
Dose adjustments may be required in elderly or debilitated patients.
Advise against abrupt discontinuation to prevent rebound arrhythmias.
Ensure patient adherence to dosing schedule and follow-up to avoid toxicity.
Avoid grapefruit and grapefruit juice which increase plasma quinidine levels.
Use with caution in patients with a history of bleeding disorders or recent hemorrhage.

Warnings

Quinidine may increase the risk of death, especially in patients with heart valve or tissue abnormalities.
Risk of severe cardiac arrhythmias including torsades de pointes due to QT interval prolongation.
Potential for life-threatening hypersensitivity reactions including anaphylaxis.
May exacerbate myasthenia gravis symptoms leading to respiratory compromise.
Not recommended for use in patients with AV block without a functioning pacemaker.
Close supervision required during initiation and dose changes due to proarrhythmic potential.
Serious hepatotoxicity has been reported; monitor for signs of liver injury.
Risk of elevated plasma concentrations and toxicity with coadministration of CYP3A4 inhibitors or grapefruit products.
Pregnancy and breastfeeding use only when clearly needed due to unknown fetal and neonatal effects.
Overdose can be fatal; symptoms include severe cardiac dysrhythmias, CNS disturbances, and gastrointestinal symptoms.
Immediate medical attention needed for signs of allergic reaction or severe adverse effects.
Abrupt withdrawal can precipitate life-threatening arrhythmias.
Use caution in patients with electrolyte disturbances that predispose to arrhythmia.
Interactions with numerous drugs necessitate comprehensive medication review before prescribing.
Use within settings equipped for cardiac monitoring and resuscitation whenever possible.

Contraindication

Known hypersensitivity to quinidine or quinine compounds.
Presence of second- or third-degree AV block unless patient has a pacemaker.
History or presence of myasthenia gravis.
History of bruising or bleeding related to prior quinidine or quinine use.
Congenital or acquired long QT syndrome to prevent life-threatening arrhythmias.
Severe thrombocytopenia or blood dyscrasias induced by quinidine.
Patients with sick sinus syndrome without pacemaker support.
Severe hepatic or renal insufficiency without appropriate dose adjustment.
Concomitant use with other QT prolonging drugs that increase risk of torsades de pointes.
Use in breastfeeding mothers due to secretion in milk and potential infant exposure.
Avoid in patients with active systemic lupus erythematosus exacerbated by quinidine.
History of severe hypersensitivity including Stevens-Johnson syndrome linked to quinidine.
Patients with electrolyte imbalances not corrected prior to initiation.
Known hypersensitivity to extended-release tablet excipients.
Infants and children except when used under strict medical supervision for severe malaria.

Drug Interactions

CYP2D6 substrates: quinidine inhibits metabolism, increasing plasma levels of drugs like propranolol, metoprolol, and tricyclic antidepressants.
CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase quinidine plasma concentrations, heightening toxicity risk.
CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce quinidine effectiveness by increasing metabolism.
Other QT-prolonging agents (e.g., amiodarone, sotalol, macrolide antibiotics): additive risk of torsades de pointes.
Digoxin: quinidine increases digoxin plasma levels by reducing renal clearance, increasing risk of digoxin toxicity.
Warfarin: quinidine may potentiate anticoagulant effects requiring INR monitoring.
Anticholinergic drugs may exacerbate quinidine’s side effects like dry mouth and urinary retention.
Neuromuscular blocking agents: quinidine may enhance blockade, necessitating dose adjustments.
Drugs affecting electrolyte balance (e.g., diuretics): altered potassium or magnesium may increase proarrhythmic risks.
Beta-blockers: possible additive cardiac depressant effects necessitating careful monitoring.
Colchicine: concurrent use may increase risk of toxicity via metabolic interactions.
Cimetidine can reduce quinidine metabolism, increasing plasma concentrations.
Statins metabolized by CYP2D6 may have altered levels when coadministered.
Avoid concomitant use with grapefruit or grapefruit juice that inhibits quinidine metabolism.
Use caution with other antiarrhythmics due to complex pharmacodynamic and pharmacokinetic interactions.

Preparations Of The Drug

Quinidine sulfate tablets: immediate-release formulations at 200 mg and 300 mg strengths.
Quinidine sulfate extended-release tablets (Quinidex Extentabs) at 324 mg for twice-daily dosing.
Intravenous quinidine gluconate for injection, administered by healthcare professionals via controlled infusion.
Brand formulations under names: Quin-G, Cardioquin, Quinora, Quinidex Extentabs, Quinaglute Dura-Tabs, Quin-Release.
Oral formulations designed for controlled absorption to maintain steady plasma levels and reduce peak-related toxicity.
Manufacturer-provided patient information leaflets with dosing and safety instructions.
Storage instructions specify room temperature, protected from moisture and heat.
Packaging includes blister packs for tablets for secure dosage and ease of administration.
Available in both sulfate and gluconate salt forms depending on route of administration.
Formulations designed with specific excipients to improve stability and bioavailability.
Extended-release tablets should not be crushed or chewed to prevent dose dumping.
Injectable formulations require dilution before administration as per protocol.
Compounding formulations occasionally prepared for specific clinical needs under strict controls.
Some brand products include unique delivery systems for improved patient adherence.
Special labeling for warnings and contraindications included to ensure safe use.